 AUSTIN, Texas, March 17, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a private company that has an abstract released today at the International Society for Apheresis meeting e-ISFA, which is being held virtually this year. The poster presentation entitled Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis given by Dr. Andrew Aswani, Consultant in Intensive Care Medicine Anesthesia at a leading London Hospital and Chief Medical Officer of Santersus AG, includes data showing that Nu.Q is an effective method for monitoring Santersus highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps NETs in sepsis. 